This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Oral semaglutide reduced HbA1c by 1.0 percentage point and produced weight loss across all age groups and diabetes durations in real-world practice across seven countries.
Why it matters
Clinical trials use strict criteria. This real-world data shows oral semaglutide works broadly in everyday patients, including older adults and those with long-standing diabetes.
The numbers in context
1,615 participants; -1.0% HbA1c at week 38 (95% CI -1.08 to -0.97); 76% on treatment at end of study; 7 countries
How the study worked
Pooled analysis of seven PIONEER REAL prospective, non-interventional, single-arm Phase 4 studies. Outcomes stratified by age, diabetes duration, dose, and baseline characteristics.
Who was studied
Adults with type 2 diabetes initiating oral semaglutide in routine clinical practice across seven countries
What this study cannot tell us
No control group. Single-arm observational design. Pooling across countries introduces heterogeneity. Patients who discontinued were not tracked for outcomes.
Read the original research
Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.
Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(1), 73-87
Citation
Rudofsky, Gottfried; Amadid, Hanan; Braae, Uffe Christian; Catrina, Sergiu-Bogdan; Kick, Anastas; Mandavya, Kabirdev; Roslind, Klaus; Saravanan, Ponnusamy; van Houtum, William; Jain, Akshay B. (2025). Oral Semaglutide Use in Type 2 Diabetes: A Pooled Analysis of Clinical and Patient-Reported Outcomes from Seven PIONEER REAL Prospective Real-World Studies.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 16(1), 73-87. https://doi.org/10.1007/s13300-024-01668-6